IBATF
INTERNATIONAL BATTERY METALS LTD.
$0.0960
-4.95%
No data for this timeframe.
Vol
Insider Activity4B / 1S
Insider Net $$4.8M
SEC Reports4
Exchange OTC·Sector Mining & Quarrying of Nonmetallic Minerals (No Fuels)·Inc. A1·CIK 0001786318·Prev Close $0.1010
Recent Activity
Jun 8, 2026
SEC
International Battery Metals Ltd. filed an 8-K announcing a conference call for its Q4 and full-year fiscal 2026 results
8-K — Impact 2/10
Jun 2, 2026
Insider
RUTLEDGE MICHAEL A acquired via exercise 450,000 shares
Chief Financial Officer
Jun 2, 2026
Insider
RUTLEDGE MICHAEL A sold 197,292 shares
Chief Financial Officer @ $0.0940 ($18.5K)
May 14, 2026
Insider
GARCIA NORMA LINDA was granted 500,000 shares
General Counsel
Apr 29, 2026
SEC
International Battery Metals Ltd. raised USD $2.8 million via a private placement of 34.3 million units at $0.08/unit to
8-K — Impact 5/10
Apr 16, 2026
SEC
International Battery Metals Ltd. (IBATF) announced a $2.8 million unregistered private placement with EV Metals VII LLC
8-K — Impact 6/10
Latest Reports
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | RUTLEDGE MICHAEL | M | $0.00 |
| Jun 2, 2026 | RUTLEDGE MICHAEL | SELL | $18.5K |
| May 14, 2026 | GARCIA NORMA | A | $0.00 |
| Apr 29, 2026 | WARNOCK JACOB | BUY | $0.00 |
| Apr 29, 2026 | WARNOCK JACOB | BUY | $2.7M |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
4 unique insiders with 11 transactions. Net insider value: $4.8M ($4.9M bought, $18.5K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | RUTLEDGE MICHAEL A | Chief Financial Officer | EXERCISE | 450,000 | — | — |
| Jun 2, 2026 | RUTLEDGE MICHAEL A | Chief Financial Officer | SELL | 197,292 | $0.0940 | $18.5K |
| May 14, 2026 | GARCIA NORMA LINDA | General Counsel | AWARD | 500,000 | — | — |
| Apr 29, 2026 | WARNOCK JACOB AARON | Director | BUY | 34,315,465 | — | — |
| Apr 29, 2026 | WARNOCK JACOB AARON | Director | BUY | 34,315,465 | $0.0800 | $2.7M |
| Feb 23, 2026 | WARNOCK JACOB AARON | Director | BUY | 26,427,053 | $0.0800 | $2.1M |
| Feb 23, 2026 | WARNOCK JACOB AARON | Director | BUY | 26,427,053 | — | — |
| Feb 12, 2026 | GARCIA NORMA LINDA | General Counsel | EXERCISE | 33,333 | — | — |
| Feb 4, 2026 | MILLS JOSEPH A | Chief Executive Officer | AWARD | 2,087,683 | — | — |
| Feb 4, 2026 | MILLS JOSEPH A | Chief Executive Officer | AWARD | 500,000 | — | — |
| Feb 4, 2026 | RUTLEDGE MICHAEL A | Chief Financial Officer | AWARD | 300,000 | — | — |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 2 neutral. Avg impact: 4.3/10.
NEUTRAL
8-K
2/10
International Battery Metals Ltd. filed an 8-K announcing a conference call for its Q4 and full-year
Jun 8, 2026
MIXED
8-K
5/10
International Battery Metals Ltd. raised USD $2.8 million via a private placement of 34.3 million un
Apr 29, 2026
BEARISH
8-K
6/10
International Battery Metals Ltd. (IBATF) announced a $2.8 million unregistered private placement wi
Apr 16, 2026
NEUTRAL
8-K
4/10
International Battery Metals Ltd. (IBATF) reported third-quarter fiscal 2026 financial results with
Feb 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.